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lopidogrel Resistance
ore Grist for the Mill*
ohn A. Cairns, MD, FRCPC, FACC,†
ohn Eikelboom, MBBS, MSC, FRACP‡
ancouver, British Columbia, and Hamilton,
ntario, Canada
lopidogrel has similar efficacy as aspirin for the prevention
f thrombotic vascular events among patients with athero-
clerotic vascular disease (1) and is a suitable alternative for
hose with aspirin intolerance or allergy. When added to
spirin, clopidogrel reduces the incidence of thrombotic
ascular outcomes among patients with acute coronary syn-
romes (2–4) and those undergoing percutaneous coronary
ntervention (PCI) (5–7). Given the wide prevalence of ath-
rosclerotic vascular diseases and the high event rates, efforts
re widespread to improve upon the therapeutic effectiveness of
lopidogrel. The observation that many patients have less than
xpected platelet inhibition with clopidogrel has given rise to
he concept of clopidogrel resistance and research to identify
nd overcome the phenomenon (8).
See page 1925
The occurrence of a cardiovascular event in a patient
rescribed clopidogrel may be designated as a treatment
ailure, which could result from noncompliance, one or
ore of the many pathophysiological mechanisms of such
vents that are independent of clopidogrel’s specific platelet
nhibition, or from inadequate clopidogrel response. Re-
ponse variability can occur because of differences in pre-
reatment platelet function (e.g., as in advancing age,
iabetes mellitus, or accelerated platelet turnover) (8) or
ecause of clopidogrel resistance. The latter term should be
eserved for situations in which there is incomplete blockade
f the platelet membrane P2Y12 receptor in a patient who is
ompliant with clopidogrel therapy. Reliable and valid
aboratory assessment of platelet inhibition is dependent
pon the baseline platelet reactivity and the choice of
latelet agonist and anticoagulant (9). Standardization of
ethods and high cost remain challenges, as does ensuring
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nd ‡McMaster University, Hamilton, Ontario, Canada.hat the chosen method is a specific measure of the degree
f P2Y12 blockade. Light-transmission aggregometry
LTA) has many shortcomings, even when adenosine
iphosphate (ADP) is used as the agonist. The platelet
asodilator-stimulated phosphoprotein-phosphorylation as-
ay using flow cytometry may be the most specific available
echnique (9).
Clopidogrel resistance may result from individual varia-
ion in clopidogrel’s absorption, metabolism, and combina-
ion with its specific platelet receptor. There is substantial
ariability in the speed and degree of absorption (7).
lopidogrel is a thienopyridine prodrug, which is converted
o its active metabolite by several enzymes of the P450
amily, including CYP3A4 and CYP2C19 (10). The active
etabolite combines irreversibly with the platelet mem-
rane P2Y12 ADP receptor, thereby inhibiting this pathway
f platelet activation, but leaving the P2Y1 ADP receptor
naffected (9). Drug–drug competition for CYP3A4 can
ecrease the production of the clopidogrel metabolite (8), as
ay polymorphisms of the CYP3A4 gene (10). The loss-
f-function CYP2C19*2 single nucleotide polymorphism,
ccurring as either a hetero- or homozygote allele, reduces
he conversion of clopidogrel to its active metabolite, and
ppears to be an important determinant of diminished
ntiplatelet effect (10,11). Achievement of optimal platelet
nhibition occurs only after several days of a maintenance
ose of 75 mg/day, but is achieved more rapidly with an oral
oading dose (600 mg is more effective than 300 mg, and
00 mg may be more effective) (12). Genetic variations in
he P2Y12 receptor may alter the therapeutic effectiveness of
lopidogrel, although conflicting results have been pub-
ished (8).
In this issue of the Journal, Trenk et al. (13) present the
esults of a pre-planned substudy of their previously pub-
ished EXCELSIOR (Impact of Extent of Clopidogrel-
nduced Platelet Inhibition During Elective Stent Implan-
ation on Clinical Event Rate) study (14), in which they
tudied 802 consecutive patients undergoing elective PCI
nd stent placement. Patients were given clopidogrel (600
g pre-PCI, then 75 mg/day maintenance) and their
esidual platelet aggregation (RPA) was measured at base-
ine and immediately pre-PCI. The median RPA pre-PCI
as 14%. The adjusted odds ratio for the composite of
eath, myocardial infarction (MI), or target lesion revascu-
arization at 30 days among patients whose RPA was above
he median of 14% was 9.6 (p  0.004) compared with
hose whose RPA was below the median. In the present
eport, 765 patients from the original cohort were grouped
ccording to pre-discharge RPAs above and below 14%.
he adjusted hazard ratio (HR) for death or MI occurring
etween discharge and 1 year was 3.7 (p  0.004), comparing
hose with RPA 14% to those below. The difference in
utcomes was accounted for primarily by the 281 patients with
drug-eluting stent (DES), among whom the HR for death or
I was 7.8 (p  0.004) comparing those with RPAs above
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Editorial Comment May 20, 2008:1935–7nd below 14%. The analogous HR in the patients with a
are-metal stent was 2 (p  0.13).
Using the EXCELSIOR cohort, the authors set out to
etermine whether the loss-of-function CYP2C19*2 poly-
orphism is associated with high RPA after the adminis-
ration of clopidogrel. They measured RPA in citrated
lood, drawn before clopidogrel (baseline), before PCI (at
east 2 h post-600 mg clopidogrel load), and before hospital
ischarge (after at least 1 maintenance dose of clopidogrel
5 mg/day). Platelets were stimulated using ADP (at 5 and
0 mol/l), with RPA determined by LTA at 5 min and
xpressed as both absolute and relative inhibition compared
ith baseline. Before PCI, RPA was inhibited by a mean of
4.2% in the *1/*1 wild-type homozygotes, but only by
1.6% in the *2 allelic variant group (p  0.001). At hospital
ischarge, the mean inhibitions of RPA were, respectively,
3.7% and 74.5% (p  0.001); this reduced difference
uggests the rate of metabolic conversion is the primary
echanism of differences in RPA. Surface protein expres-
ion of a number of markers of platelet activation after
timulation by ADP 20 mol/l was reduced pre-PCI and
re-discharge, more so in the *1/*1 group than in the *2
llelic variant group. There were no differences in baseline
PA or surface marker expression, ruling out this important
ource of variability (7).
The authors were unable to determine if the *2 allelic
ariant is predictive of death or MI. The incidence at 1 year
as 3.4% among the *1/*1 homozygotes compared with
.0% among the *1/*2 heterozygotes (p  0.372). Among
he patients with at least 1 DES, the incidence of death or
I was 2.1% among the homozygotes and 3.3% among the
arriers. The rates of these events were low, and there was
nsufficient power to detect modest but still important
ifferences between the groups, although it might have been
elpful to look at the overall incidence of death or MI from
he PCI to 1 year.
Do these observations enhance our understanding of clopi-
ogrel resistance? Do they provide new approaches to patient
anagement? Do they open new avenues of research? The
bservations of the predictive value of high RPA after clopi-
ogrel therapy for subsequent thrombotic events extend the
hort-term observations of the EXCELSIOR study (14) and
onfirm those made in other sizeable studies (15,16). However,
or the present, the clinical utility of the observations is
inimal. The determination of RPA by LTA is a complex test
ith considerable variability from one laboratory to another,
nd it is not specific for clopidogrel’s blockade of the P2Y12
eceptor (9). The clinician needs a rapid, inexpensive, reli-
ble, and specific test for the pre-PCI assessment of short-
nd long-term risk. A finding of high short-term risk might
rompt the addition of an intravenous glycoprotein IIb/IIIa
nhibitor during the procedure. A finding of high long-term
isk (perhaps those patients with the highest RPAs and
hose receiving a DES) might prompt raising clopidogrel
ose or using prasugrel, a more potent thienopyridine withess response variability (17). Prasugrel has a greater overallisk of bleeding, but if patients with relatively high clopi-
ogrel resistance could be identified, it is conceivable that
ubstituting prasugrel might increase efficacy without sub-
tantially increasing bleeding. Clinical trials of various
anagement strategies incorporating assessments of platelet
nhibition are required to sort out the options for patients
ith apparent clopidogrel resistance. For the present, pro-
essional societies recommend that platelet function assess-
ent be confined to research studies. New drugs such as
ZD6140 and cangrelor, which directly target the P2Y12
eceptor and are reversible, may provide options with less
esponse variability than clopidogrel, obviating complex and
xpensive assessments of platelet reactivity (18).
The observations of greater RPA among the carriers of
he *2 allelic variant provide extensive new data on the
mpact this loss-of-function single nucleotide polymor-
hism has on clopidogrel’s platelet inhibition. The effect in
eterozygotes is a reduction and slowing of clopidogrel
ction. Additional experiments are required to clarify
hether a higher loading dose and/or longer-term admin-
stration of clopidogrel might lead to greater inhibition of
esidual platelet reactivity. Measurements of the clopidogrel
etabolite would also help to clarify the mechanism of
educed inhibition. The mean RPA of the carriers of the *2
llele is higher than that of the *1/*1 homozygotes, but there
s extensive overlap of the values in the 2 groups. Therefore,
ven if the genotyping could be accomplished at reasonable
peed and cost, intensification of antithrombotic therapy
ight subject many *2 patients to unnecessary bleeding
isk, and more intense therapy would be denied to many
mong the *1/*1 homozygotes with relatively high RPA.
he clinical importance of the observations will remain
ncertain unless a clear relationship can be established
etween the presence of the allelic variant and increased
hrombotic vascular events.
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